Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Operating Income (2016 - 2021)

GT Biopharma (GTBP) has disclosed Operating Income for 12 consecutive years, with -$18.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Operating Income fell 297.65% to -$18.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$57.5 million, a 950.31% decrease, with the full-year FY2025 number at -$12.4 million, up 13.52% from a year prior.
  • Operating Income was -$18.2 million for Q4 2021 at GT Biopharma, down from -$6.0 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $263.0 million in Q4 2019 to a low of -$126.9 million in Q3 2017.
  • A 5-year average of $2.7 million and a median of -$4.2 million in 2019 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: crashed 4914.07% in 2017, then surged 126.38% in 2020.
  • GT Biopharma's Operating Income stood at -$5.9 million in 2017, then grew by 12.46% to -$5.2 million in 2018, then soared by 5200.5% to $263.0 million in 2019, then plummeted by 96.5% to $9.2 million in 2020, then tumbled by 297.65% to -$18.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Operating Income are -$18.2 million (Q4 2021), -$6.0 million (Q3 2021), and -$4.4 million (Q2 2021).